

### **Correction to *Lancet Gastroenterol Hepatol* 2017; 2: 103–11**

Yang JD, Mohamed EA, Abdel Aziz AO, et al. Characteristics, management, and outcomes of patients with hepatocellular carcinoma in Africa: a multicountry observational study from the Africa Liver Cancer Consortium. *Lancet Gastroenterol Hepatol* 2017; 2: 103–11—In table 1, the denominators for BCLC stage for the Egypt column should read 1087 and for Other African countries should read 545. These corrections have been made online as of July 6, 2022.

### **Correction to *Lancet Gastroenterol Hepatol* 2021; 6: 448–58**

Andrieux-Meyer I, Tan S-S, Thanprasertsuk S, et al. Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trial. *Lancet Gastroenterol Hepatol* 2021; 6: 448–58—In table 4 of this Article, the title of the second column of data should read “Genotype 3” and the title of the fourth column of data should read “HCV prior treatment”. These corrections have been made online as of July 6, 2022.

### **Correction to *Lancet Gastroenterol Hepatol* 2022; 7: 736–46**

Ly Y, Chen H, Luo B, et al. Transjugular intrahepatic portosystemic shunt with or without gastro-oesophageal variceal embolisation for the prevention of variceal rebleeding: a randomised controlled trial. *Lancet Gastroenterol Hepatol* 2022; 7: 736–46—The last line of the second paragraph of the Results section should read “Five (31%) of 16 patients in the TIPS plus embolisation group and nine (43%) of 21 patients in the TIPS group received drugs and endoscopic treatment as primary therapy for the management of rebleeding.” This correction has been made as of July 6, 2022.

### **Correction to *Lancet Gastroenterol Hepatol* 2022; 7: 627–47**

GBD 2019 Colorectal Cancer Collaborators. Global, regional, and national burden of colorectal cancer and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet Gastroenterol Hepatol* 2022; 7: 627–47—The affiliation details for Mihajlo Jakovljevic have been corrected online as of July 6, 2022.